Reumatologia: pesquisas atuais
Acesso livre
ISSN: 2161-1149 (Printed)
ISSN: 2161-1149 (Printed)
Yan Liu*, Chunmei Yan
Background: Lung cancer is a common clinical malignant tumor of the respiratory system. When the disease progresses to the late stage, distant metastasis often occurs, and the metastatic lesions are mostly multiple metastases. Bone is a common distant metastasis site of lung cancer, which can cause complications such as hypercalcemia, osteoporosis, pathological fracture, nerve compression, and severe pain and limited activity. It is one of the important reasons for the decline of quality of life in patients with lung cancer. At present, there is no specific treatment for pain caused by bone metastasis of lung cancer. Drug analgesia is generally used, but there are still some patients with pain symptoms cannot be significantly improved.
Objective: The effect of dezocine combined with oxycodone on the pain score (NRS) of patients with severe cancer pain caused by bone metastasis of advanced lung cancer was analyzed.
Methods: 100 patients were randomly divided into control group (50 cases) and observation group (50 cases). The control group was given intramuscular injection of dezocine for analgesia, and the observation group was given oral oxycodone hydrochloride controlled release tablets on the basis of intramuscular injection of dezocine for analgesia. The changes of NRS score and EORTCQLQ-C30 score were compared. The levels of β-EP and 5-HT were detected.
Results: The pain relief rate and analgesic effective rate of the observation group were better than those of the control group, with statistical significance (p<0.05). The NRS score was similar before treatment (p>0.05). After 1D, 3D and 7D of treatment, the NRS score of the two groups decreased significantly (p<0.05), and the NRS score of the observation group was lower than that of the control group after 1D, 3D and 7D of treatment (p<0.05). The number of outbreaks of pain in the observation group was less than that in the control group, the first stable time of pain control was shorter than that in the control group, and the 24 h sleep increase time was longer than that in the control group, with statistical significance (p<0.05). After treatment, β -EndocaPeptide (β-EP) in the two groups was significantly increased (p<0.05), and 5-hydroxytryptamine (5-HT) was significantly decreased (p<0.05). After treatment, β-EP in the observation group was higher than that in the control group, and 5-HT was lower than that in the control group (p<0.05). After treatment, the scores of overall health status, function and nausea and vomiting in symptomatic areas of the two groups were significantly higher than those before treatment. The scores of pain, insomnia and loss of appetite in symptomatic areas were significantly lower than those before treatment. Other scores were similar to those before treatment (p>0.05). The scores of overall health status function and nausea and vomiting in symptomatic areas of the observation group after treatment were higher than those of the control group. The scores of pain, insomnia and loss of appetite in symptomatic areas were lower than those of the control group. Other scores were similar to those of the control group (p>0.05). The adverse reactions of the two groups were similar (p>0.05).
Conclusion: Dezocine combined with oxycodone in the treatment of severe cancer pain caused by bone metastasis of advanced lung cancer can effectively relieve pain, regulate the expression of pain factors and improve the quality of life, but the adverse reactions should be observed.